Developing a wildlife health intelligence and vaccine distribution system. This project aims to establish an industry-linked pipeline for vaccines to be delivered to animals in edible baits and a near real-time monitoring system for assessing the impact of management actions. This project will develop ultrasensitive diagnostic tests and incorporate biomarkers into baits from Australia's leading pest animal control company. Bait uptake and disease status in the field will be monitored using artif ....Developing a wildlife health intelligence and vaccine distribution system. This project aims to establish an industry-linked pipeline for vaccines to be delivered to animals in edible baits and a near real-time monitoring system for assessing the impact of management actions. This project will develop ultrasensitive diagnostic tests and incorporate biomarkers into baits from Australia's leading pest animal control company. Bait uptake and disease status in the field will be monitored using artificial intelligence technology developed in Tasmania. This integrated wildlife health intelligence and scalable vaccine platform can help protect the iconic Tasmanian devil from disease and increase Australia's preparedness for looming threats to the livestock industry such as African swine fever.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent ....A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent enteric parasite identified globally in dogs. Infection rates can be as high as 75% in puppies. Current treatments are failing due to poor efficacy, resistance and poor adherence to treatment schedules. We have identified a novel, extremely rapid acting series of compounds capable of single shot eradication of Giardia.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100035
Funder
Australian Research Council
Funding Amount
$4,743,710.00
Summary
ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to devel ....ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to develop ‘smart’ probes and ‘smart’ scanning, harnessing the digital revolution for better, cost effective diagnostic imaging and improved health outcomes.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC220100050
Funder
Australian Research Council
Funding Amount
$4,508,426.00
Summary
ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance (ARC CEA-StAR). The ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance aims to develop industry-led solutions and train a new generation of researchers to combat the impact of antimicrobial resistance (AMR) on agribusiness and the environment.
AMR is a global health and economic threat that epitomises the need for a ‘One Health’ collaborative approach encompassi ....ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance (ARC CEA-StAR). The ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance aims to develop industry-led solutions and train a new generation of researchers to combat the impact of antimicrobial resistance (AMR) on agribusiness and the environment.
AMR is a global health and economic threat that epitomises the need for a ‘One Health’ collaborative approach encompassing the interconnection between people, animals, plants, and their shared environment.
Expected outcomes of this collaborative program include a cohort of researchers trained in industry-relevant techniques, furnishing solutions to partner-defined AMR challenges, and providing significant benefits by positioning Australia as a global leader in reducing AMR.Read moreRead less
Understanding disease resistance gene evolution across the Brassicaceae. Pan genomes represent the diversity of a species, including structural and sequence variation, which cannot be provided by a reference genome alone. In this project we will characterise resistance gene diversity across the Brassicaceae pan genomes. Through comparison with resistance gene diversity in cultivated Brassica species we will understand selection underlying resistance gene evolution in wild species and subsequent ....Understanding disease resistance gene evolution across the Brassicaceae. Pan genomes represent the diversity of a species, including structural and sequence variation, which cannot be provided by a reference genome alone. In this project we will characterise resistance gene diversity across the Brassicaceae pan genomes. Through comparison with resistance gene diversity in cultivated Brassica species we will understand selection underlying resistance gene evolution in wild species and subsequent domestication and breeding. Knowledge on how variation affects disease susceptibility, especially to the devastating fungal pathogen blackleg, and contributes to phenotypic variation, will lead to improved plant protection strategies and increased crop resilience.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE240100388
Funder
Australian Research Council
Funding Amount
$437,977.00
Summary
Ecological and phylogenomic insights into infectious diseases in animals. This project aims to address major knowledge gaps in our understanding of Clostridium difficile, a leading cause of severe gastrointestinal disease in animals. The project is expected to define the epidemiology of C. difficile infection in Australian horses, characterise the genetic and phenotypic traits of C. difficile strains causing equine disease and develop a new tool for enhanced genomic tracking of C. difficile in a ....Ecological and phylogenomic insights into infectious diseases in animals. This project aims to address major knowledge gaps in our understanding of Clostridium difficile, a leading cause of severe gastrointestinal disease in animals. The project is expected to define the epidemiology of C. difficile infection in Australian horses, characterise the genetic and phenotypic traits of C. difficile strains causing equine disease and develop a new tool for enhanced genomic tracking of C. difficile in animals. These outcomes will support strategies by the veterinary sector to improve the detection, prevention and control of C. difficile infections in animals, providing long-term socio-economic benefits arising from reduced incidence and mortality associated with C. difficile infections in Australian horses and livestock.Read moreRead less
Enhancing biopharmaceuticals: A disruptive bioseparation resin technology. This project aims to develop an innovative and disruptive platform technology for designing and manufacturing tailor-made high-performance bioseparation resins to enhance biopharmaceuticals manufacturing. Bacterial cell factories will be developed to enable biotechnological production of innovative polyester bead-based bioseparation resins, which will revolutionise manufacturing of biopharmaceuticals. Expected outcomes o ....Enhancing biopharmaceuticals: A disruptive bioseparation resin technology. This project aims to develop an innovative and disruptive platform technology for designing and manufacturing tailor-made high-performance bioseparation resins to enhance biopharmaceuticals manufacturing. Bacterial cell factories will be developed to enable biotechnological production of innovative polyester bead-based bioseparation resins, which will revolutionise manufacturing of biopharmaceuticals. Expected outcomes of this project are cost-effective and strongly enhanced approaches for biopharmaceuticals recovery, thereby providing significant benefits to accelerate research and development in early stage discovery and manufacture of biologics, therapeutic proteins and vaccines.Read moreRead less
Pyruvate provision for mitochondrial respiration in plants. This project aims to generate new knowledge about pyruvate provision for respiration in plants as it is a major pathway of carbon loss from plants. It will address specific gaps in knowledge about how pyruvate is provided to mitochondria for respiration, how channelling of pyruvate is achieved between components in this pathway and it will seek to engineering a new pyruvate supply pathway to change respiratory processes in plants. It wi ....Pyruvate provision for mitochondrial respiration in plants. This project aims to generate new knowledge about pyruvate provision for respiration in plants as it is a major pathway of carbon loss from plants. It will address specific gaps in knowledge about how pyruvate is provided to mitochondria for respiration, how channelling of pyruvate is achieved between components in this pathway and it will seek to engineering a new pyruvate supply pathway to change respiratory processes in plants. It will develop techniques for analysis of metabolic processes in plants and genetic proof for assumptions of how plant respiration works. Benefits will be training of early career researchers, enhanced international reputation of Australian plant science and new approaches to engineer respiratory rate in plants.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH220100017
Funder
Australian Research Council
Funding Amount
$4,808,669.00
Summary
ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The progra ....ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.Read moreRead less